Astria Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2019 12 months to Dec 31, 2019
Operating activities
Net loss
Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization
Non-cash portion of acquired in-process research and development
Stock-based compensation expense
Gain on disposal of property and equipment
Services received in non-monetary exchange
Net gain on warrants inherited in acquisition of Quellis
Right-of-use asset- operating lease
Accretion of discount/premium on investment securities
Other non-cash items
Changes in assets and liabilities:
Prepaid expenses and other assets
Right-of-use asset-operating
Lease liability - operating lease
Accounts payable
Accrued expenses
Other liabilities

Net cash used in operating activities
Investing activities
Purchases of short-term investments
Sales and maturities of short-term investments
Cash acquired in acquisition of Quellis
Purchases of property and equipment
Net cash (used in) provided by investing activities

Financing activities
Proceeds from public offering, net of underwriting discounts and issuance costs
Proceeds from exercise of common stock options and warrants
Proceeds from private offering of public equity, net of issuance costs
Proceeds from at-the-market offering, net of issuance costs
Proceeds from exercise of stock options
Proceeds from exercise of stock options and warrants
Net cash provided by financing activities

Net (decrease) increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period
At-the-market issuance costs included in current liabilities
Operating lease right-of-use assets obtained in exchange for operating lease liabilities
Conversion of Series X Preferred Stock into common stock
Non-cash dividend on convertible preferred stock
Reclassification of warrant liability to additional paid-in capital
Purchases of property and equipment in accounts payable and accrued liabilities
Public offering issuance costs in accrued expenses

Comments